[用90Y-替伊莫单抗进行淋巴瘤的放射免疫治疗] - Suppr

[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].

作者信息

Setoain X, López-Guillermo A, Ruiz A, Pons F

机构信息

Medicina Nuclear, Hospital Clínic i Provincial de Barcelona, Barcelona.

出版信息

Rev Esp Med Nucl. 2006 Jan-Feb;25(1):55-68; quiz 69-70.. doi: 10.1157/13083353.

DOI:10.1157/13083353

PMID:16540015

Abstract

摘要

相似文献

[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].

Rev Esp Med Nucl. 2006 Jan-Feb;25(1):55-68; quiz 69-70.. doi: 10.1157/13083353.

[Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status].

Rev Esp Med Nucl. 2006 Jan-Feb;25(1):42-54. doi: 10.1157/13083351.

Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

J Nucl Med. 2003 Mar;44(3):465-74.

A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5652s-5660s. doi: 10.1158/1078-0432.CCR-07-1060.

Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S91-5. doi: 10.1007/s002800100312.

90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.

Expert Opin Biol Ther. 2004 Aug;4(8):1323-31. doi: 10.1517/14712598.4.8.1323.

[Radioimmunotherapy with (90)Y-ibritumomab tiuxetan (Zevalin). Spanish Nuclear Medicine Society].

Rev Esp Med Nucl. 2010 Jan-Feb;29(1):50-2. doi: 10.1016/j.remn.2009.11.003. Epub 2009 Dec 5.

[Contribution of radioimmunotherapy to the treatment of lymphoma].

Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8. doi: 10.1016/j.pharma.2008.09.003. Epub 2008 Nov 8.

Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

Semin Oncol. 2003 Dec;30(6 Suppl 17):23-8. doi: 10.1053/j.seminoncol.2003.10.003.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

J Clin Oncol. 2002 May 15;20(10):2453-63. doi: 10.1200/JCO.2002.11.076.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献